Clinical Trials Browser

Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05636514 2026-03-18

CELESTIAL-MDS

Phase 1 Recruiting

12 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT05673200 2026-03-18

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Phase 1 Recruiting

32 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06484062 2026-03-16

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Phase 1 Recruiting

54 enrolled

MyeloidOther hematologic neoplasm

GATA2 Deficiency, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04953897 2026-03-10

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

Phase 1 Recruiting

18 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06191978 2026-02-18

A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Phase 1 Recruiting

40 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06177171 2026-02-02

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

Phase 1 Recruiting

18 enrolled

BRCA1 Mutation

NCT05010772 2026-01-14

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

Phase 1 Recruiting

125 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06327685 2026-01-08

Avapritinib With Decitabine in Patients With SM-AHN

Phase 1 Recruiting

34 enrolled

MyeloidOther hematologic neoplasm

Systemic Mastocytosis With an Associated Hematologic Neoplasm

NCT03922555 2025-12-18

ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas

Phase 1 Recruiting

18 enrolled

CNS

Central Nervous System Neoplasms

NCT05178693 2025-11-24

LANTana

Phase 1 Recruiting

27 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT02998567 2025-08-17

HyPeR

Phase 1 Recruiting

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

CELESTIAL-MDS

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

Avapritinib With Decitabine in Patients With SM-AHN

ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas

LANTana

HyPeR